journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Urology

journal
https://www.readbyqxmd.com/read/27904653/inadvertent-ureteric-placement-and-successful-readjustment-of-a-urodynamic-catheter-via-fluoroscopy-in-a-spinal-injury-patient
#1
Michael S Floyd, Helen Russell, Jenny Goodman, Chalil P Vinod, Melissa C Davies
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27904652/urolift-a-new-minimally-invasive-treatment-for-benign-prostatic-hyperplasia
#2
REVIEW
Patrick Jones, Bhavan P Rai, Omar Aboumarzouk, Bhaskar K Somani
'UroLift' has emerged as a new minimally-invasive nonablative surgical technique for benign prostatic hyperplasia (BPH). We discuss the procedure, cost, evidence, advantages and disadvantages of this procedure. It is a novel technology suitable for a selected group of patients that allows for a bespoke treatment for men with BPH.
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27904651/sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#3
REVIEW
Thomas A Schmid, Martin E Gore
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer (mRCC) after a phase III trial showed superiority compared with interferon alpha (IFN-α). Sunitinib has also shown activity in second-line treatment in several trials. Most of the combination trials with sunitinib with various agents have led to considerable toxicity without improving efficacy...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27904650/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-clinical-trial-evidence-and-experience
#4
REVIEW
Jose Manuel Ruiz-Morales, Daniel Y C Heng
The treatment of metastatic renal cell carcinoma (mRCC) is rapidly changing. During first-line treatment with targeted therapy, patients ultimately develop resistance to therapy and the disease progresses. Recently, cabozantinib has demonstrated a better response rate, progression-free survival and overall survival compared with everolimus after failure of prior targeted therapy in patients with advanced or metastatic renal cell carcinoma (RCC). Cabozantinib is a small-molecule tyrosine kinase inhibitor (TKI)...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27904649/fasciocutaneous-flap-reinforcement-of-ventral-onlay-buccal-mucosa-grafts-enables-neophallus-revision-urethroplasty
#5
Stelios C Wilson, John T Stranix, Kiranpreet Khurana, Shane D Morrison, Jamie P Levine, Lee C Zhao
BACKGROUND: Urethral strictures or fistulas are common complications after phalloplasty. Neourethral defects pose a difficult reconstructive challenge using standard techniques as there is generally insufficient ventral tissue to support a graft urethroplasty. We report our experience with local fasciocutaneous flaps for support of ventrally-placed buccal mucosal grafts (BMGs) in phalloplasty. METHODS: A retrospective review of patients who underwent phalloplasty and subsequently required revision urethroplasty using BMGs between 2011 and 2015 was completed...
December 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27695530/nivolumab-in-the-treatment-of-advanced-renal-cell-carcinoma-clinical-trial-evidence-and-experience
#6
REVIEW
Alessia Mennitto, Paolo Grassi, Raffaele Ratta, Elena Verzoni, Michele Prisciandaro, Giuseppe Procopio
Renal cell carcinoma (RCC) is considered an immunogenic tumor with a prominent dysfunctional immune cell infiltrate, unable to control tumor growth. Cytokine-based immunotherapies, including interferon-α and interleukin-2, have been used for the treatment of metastatic RCC (mRCC). Long-term responses and complete remissions were observed, but durable clinical benefit efficacy in the overall population was limited and associated with significant toxicity. As a consequence, new generation agents targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways replaced interferon alpha (IFN-α)...
October 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27695529/oxidation-reduction-potential-of-semen-what-is-its-role-in-the-treatment-of-male-infertility
#7
Ashok Agarwal, Shubhadeep Roychoudhury, Kimberly B Bjugstad, Chak-Lam Cho
The diagnosis of male infertility relies largely on conventional semen analysis, and its interpretation has a profound influence on subsequent management of patients. Despite poor correlation between conventional semen parameters and male fertility potential, inclusion of advanced semen quality tests to routine male infertility workup algorithms has not been widely accepted. Oxidative stress is one of the major mediators in various etiologies of male infertility; it has deleterious effects on spermatozoa, including DNA damage...
October 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27695528/management-of-equivocal-early-fournier-s-gangrene
#8
Mohamed El-Shazly, Mohamed Aziz, Hamdy Aboutaleb, Shady Salem, Eid El-Sherif, Mohamed Selim, Mohamed Sultan, Mohamed Omar, Tarek Abd Elbaky, Fouad Zanaty, Talal Alenezi, Abdelazeem Ghobashi, Adel Allam
BACKGROUND: Fournier's gangrene (FG) is an acute progressive necrotizing fasciitis of the genital area and perineum with possible extension to the abdominal wall. Surgical debridement is the gold standard management modality of established patients. Equivocal (early) FG represents a challenge in diagnosis. The objective of this study was to compare conservative management and early exploration in cases of equivocal (early) FG. METHODS: This was an observational study where data of all patients diagnosed as early FG in our departments over 4 years (2011-2015) were enrolled...
October 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27247632/diseases-masking-and-delaying-the-diagnosis-of-urogenital-tuberculosis
#9
Carlos Altez-Fernandez, Carlos Seas, Luis Zegarra, Cesar Ugarte-Gil
No abstract text is available yet for this article.
June 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27247631/molecular-substratification-of-bladder-cancer-moving-towards-individualized-patient-management
#10
REVIEW
Anirban P Mitra
Despite advances in surgical techniques, perioperative therapies and postoperative management, outcomes for patients with bladder cancer have largely remained unchanged. Current management of bladder cancer still relies on pathologic staging that does not always reflect the risk for an individual patient. Studies assessing molecular alterations in individual tumors are offering insights into the myriad of cellular pathways that are deregulated in bladder tumorigenesis and progression. Alterations in pathways involved in cell-cycle regulation, apoptosis, cell signaling, angiogenesis and tumor-cell invasion have been shown to influence disease behavior...
June 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27247630/novel-immunotherapeutic-approaches-to-the-treatment-of-urothelial-carcinoma
#11
REVIEW
Akhil Muthigi, Arvin K George, Sam J Brancato, Piyush K Agarwal
Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma...
June 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27247629/collagenase-clostridium-histolyticum-in-the-management-of-peyronie-s-disease-a-review-of-the-evidence
#12
REVIEW
Elizabeth J Traore, William Wang, Faysal A Yafi, Wayne J G Hellstrom
OBJECTIVES: Peyronie's disease (PD) is a connective tissue disorder resulting in the abnormal accumulation of scar or plaques in the tunica albuginea of the penis. The condition is characterized by two phases: an active, inflammatory phase, and a stable, chronic phase. Collagenase Clostridium histolyticum (CCH) was isolated in the mid-1900s and postulated as a potential pharmacologic strategy for breaking down the abnormal connective tissue plaques of PD. Prior to the introduction of CCH, a wide variety of treatment modalities for PD were used in clinical practice, including oral and topical medications, intralesional injections, electromotive drug administration, extracorporeal shockwave therapy, traction, and invasive surgery, all with variable results...
June 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27247628/evidence-of-the-efficacy-and-safety-of-the-thulium-laser-in-the-treatment-of-men-with-benign-prostatic-obstruction
#13
REVIEW
Yana Barbalat, Marissa C Velez, Christopher I Sayegh, Doreen E Chung
In 2005, the high power thulium laser was introduced for the surgical treatment of benign prostatic obstruction. It has several properties that confer theoretical advantages over other lasers used for the same indication, such as technical versatility and a relatively small zone of thermal damage. Studies using the 70-150 W thulium laser systems demonstrate good efficacy of these procedures with low morbidity and few complications even in higher risk patients. Different techniques have been employed to treat the prostate with this technology, including enucleation, vapoenucleation, vaporization and resection...
June 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27247627/clinical-experience-with-radium-223-in-the-treatment-of-patients-with-advanced-castrate-resistant-prostate-cancer-and-symptomatic-bone-metastases
#14
REVIEW
Christina Hague, John P Logue
The treatment of metastatic castrate-resistant prostate cancer (mCRPC) has grown over the past decade. The majority of patients develop bone metastases, which pose a significant burden on morbidity and mortality, especially skeletal-related events. Whilst demonstrating a favourable safety profile and improving symptoms, radiopharmaceuticals have until recently failed to show a survival benefit. However, since the large phase III randomized ALSYMPCA trial, the calcium mimetic properties of radium-223 (Ra223) have improved patients' quality of life and improved survival whilst keeping toxicities to a minimum...
June 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27247626/risk-factors-for-infectious-readmissions-following-radical-cystectomy-results-from-a-prospective-multicenter-dataset
#15
Sij Hemal, Louis S Krane, Kyle A Richards, Michael Liss, A Karim Kader, Ronald L Davis
INTRODUCTION: Radical cystectomy (RC) is the gold standard treatment for muscle-invasive bladder cancer. This procedure has a high rate of perioperative complications, many of which are infectious in nature. The objective of our study was to evaluate demographic, intrinsic and extrinsic patient variables associated with developing readmission within 30 days due to infectious complications following RC. METHODS: We acquired data available from the American College of Surgeons National Surgical Quality Improvement Program...
June 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27034727/an-update-on-the-role-of-testosterone-replacement-therapy-in-the-management-of-hypogonadism
#16
REVIEW
Geoffrey Hackett
While US testosterone prescriptions have tripled in the last decade with lower trends in Europe, debate continues over the risks, benefits and appropriate use of testosterone replacement therapy (TRT). Some authors blame advertising and the availability of more convenient formulations whilst other have pointed out that the routine testing of men with erectile dysfunction (a significant marker of cardiovascular risk) and those with diabetes would inevitably increase the diagnosis of hypogonadism and lead to an increase in totally appropriate prescribing...
April 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27034726/-mini-ultra-micro-nomenclature-and-cost-of-these-new-minimally-invasive-percutaneous-nephrolithotomy-pcnl-techniques
#17
REVIEW
Anna Wright, Nick Rukin, Daron Smith, Jean De la Rosette, Bhaskar K Somani
New minimally invasive percutaneous nephrolithotomy (PCNL) techniques have changed the management of renal stones. We discuss the technological advances in PCNL and explain the meaning, requirements and set up costs for each of these 'newer' techniques.
April 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27034725/the-role-of-neoadjuvant-therapy-in-the-management-of-locally-advanced-renal-cell-carcinoma
#18
REVIEW
Leonardo D Borregales, Mehrad Adibi, Arun Z Thomas, Christopher G Wood, Jose A Karam
In the past decade, the armamentarium of targeted therapy agents for the treatment of metastatic renal cell carcinoma (RCC) has significantly increased. Improvements in response rates and survival, with more manageable side effects compared with interleukin 2/interferon immunotherapy, have been reported with the use of targeted therapy agents, including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, axitinib), mammalian target of rapamycin (mTOR) inhibitors (everolimus and temsirolimus) and VEGF receptor antibodies (bevacizumab)...
April 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27034724/androgen-deprivation-therapy-and-cardiovascular-disease-what-is-the-linking-mechanism
#19
REVIEW
Piotr Zareba, Wilhelmina Duivenvoorden, Darryl P Leong, Jehonathan H Pinthus
The past decade has brought increased awareness of the potential adverse effects of androgen deprivation therapy (ADT) in men with prostate cancer. Arguably the most important and controversial of these is the increased risk of cardiovascular morbidity and mortality. Although multiple observational studies have shown that men treated with ADT are at increased risk of developing atherosclerotic cardiovascular disease, our understanding of the biological mechanisms that might underlie this phenomenon is still evolving...
April 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27034723/a-review-of-the-efficacy-and-safety-of-mirodenafil-in-the-management-of-erectile-dysfunction
#20
REVIEW
Min Chul Cho, Jae-Seung Paick
Erectile dysfunction (ED) is a common disorder that can jeopardize quality of life and the partnership of patients and their sexual partners. The advent of oral phosphodiesterase type 5 inhibitors (PDE5Is) has revolutionized a treatment for ED, and they are recognized as the first-line therapy for ED, regardless of its etiology. Mirodenafil, a second-generation PDE5I, has biochemical profiles such as high affinity for PDE5 and high selectivity for PDE5 over other PDE isoforms, compared to other existing PDE5Is such as sildenafil, vardenafil and tadalafil...
April 2016: Therapeutic Advances in Urology
journal
journal
42175
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"